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ABSTRACT
Breast cancer is a serious health concern and still a leading cause of death among women in the world. To explore the
complexity of this cancer, we performed microarray analysis on highly selective cancer and normal breast tissues. The
aim of this study was to identify differentially expressed genes between both tissues and to elucidate further molecular
pathways involved in breast cancer carcinogenesis. Genome-wide expression profiling was performed on fifteen cancer
and five normal breast tissues using the Affymetrix GeneChip® Human Gene 1.0 ST array. Supervised hierarchical
cluster analysis using filtering parameters of -1.5 to 1.5 fold-change and p-value with False Discovery Rate < 0.05
revealed 404 up-regulated and 463 down-regulated genes. Pathway analysis revealed the significant genes were involved
in cell cycle regulation, DNA repair, Hedgehog pathway, histone phosphorylation, TRRAP/Tip60 chromatin remodelling
and apoptosis regulation. Among the top 10 significantly overexpressed genes were CENPF, DTL and MK167 and these
were related to cell cycle regulation. Among the top 10 significant down-regulated genes, HOXA5 and NRG1 were found
to be associated with Wnt signalling pathway and ErbB signalling pathway respectively. Aberrations in these genes are
likely to promote breast cancer carcinogenesis. Our current findings highlighted the importance of differentially
expressed genes in breast cancer and their molecular pathways that linked these genes. Further studies are required to
validate our findings using larger sample size.
INTRODUCTION
Breast cancer is the most frequent cancer and a serious
health concern among females (1, 2). This cancer accounts
for more than 410,000 deaths among females each year (3)
and 14% of cancer deaths (1). The incidence is substantially
increasing in Asian countries compared to other regions of
the world (4). In Malaysia, breast cancer was the most
common cancer in females with a total of 31.3% in 2005 and
the percentage increased to 33.8% in 2007. Among the three
major races in this country, the incidence was reported to
be highest in Chinese compared to Malays and Indians (2).
Breast cancer is a heterogeneous and complex disease
(5). It is caused by both genetic and epigenetic alterations
(6). In the past few years, microarray studies have been
applied to improve our understanding on the pathogenesis
and heterogeneity of breast cancer. Breast cancer has been
classified by gene expression studies into luminal A, luminal
B, HER2/neu overexpressed, basal-like and normal breast-
like tumour subtypes (7). This technology has also been
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used to predict patients’ prognosis, treatment selection
and therapeutic target identification in breast cancer (8).
The Oncotype DX assay (Genomic Health, Redwood City,
California) is an example of an FDA approved assay that
contains 21 significant genes identified from gene
expression profiling. These signatures were used to select
women who would benefit from the addition of
chemotherapy to tamoxifen (9, 10). In addition, the
Mammaprint assay (Agendia, Amsterdam, The
Netherlands) that contains 70 significant genes has also
been developed to predict risk of distant metastasis in breast
cancer patients and identify the patients who would benefit
from systemic chemotherapy (11, 12). Until today, these
two assays have yet to be proven to be sensitive and
reliable for all high risk women (13).
Microarray has also been used to identify the
differentially expressed genes between preoperative
biopsies and postoperative breast tumours in a previous
study (14). Several early response stress-related genes such
as FOSB and DUSP1 and cancer related genes including
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MAPK, MALAT1 and RASD1 were found to be differentially
expressed. Another study used whole-genome cDNA-
mediated Annealing, Selection, extension and Ligation
(DASL) assay to identify differentially expressed genes
between FFPE and fresh frozen breast tissues (15). They
have suggested that results from FFPE samples should
not be directly compared with results from fresh frozen
breast tissues. This was because the formalin fixation used
in FFPE samples may induce significant gene expression
changes. In Malaysia, a microarray study on 43 paired
samples revealed 33 significantly expressed genes
including CD24, CD36, CD9, TACSTD1, TACSTD2, HBB,
LEP, LPL, AKR1C1, AKR1C2 and AKR1C3 in breast
tumours compared to normal breast tissues (16). However
the study used whole tissues that were likely to contain
both cancer and non-cancerous tissues and there was no
validation step done to confirm their results.
Despite the technological advances in genomics and
transcriptomics, genome-wide microarray based expression
analysis is still a reliable tool to allow better understanding
of the breast cancer. In this study, we used gene expression
profiling by microarray to identify the differentially
expressed genes and to determine the molecular pathways
that linked these genes in macro- and micro-dissected breast
cancer tissues.
MATERIALS AND METHODS
CLINICAL SAMPLES
Subjects were recruited from the Universiti Kebangsaan
Malaysia Medical Centre (UKMMC) and Hospital Kuala
Lumpur (HKL), Malaysia. Fifteen primary breast tumours
and five normal breast tissue samples were collected from
14 Malays and six Chinese patients. All subjects
volunteered to participate in this study and signed the
informed consent forms. Only patients who have not
received chemotherapy or hormone therapy were included.
All samples were properly collected and placed in liquid
nitrogen before being transferred to the biobank at the
UKM Molecular Biology Institute (UMBI) for processing
and storage. Tissues were stored at -80°C until further
analysis.
All tissues were sectioned into 5 to 7 µm thickness
using a cryostat (Microtome Cryostat HM 550; MICROM
International GmbH, Walldorf, Germany) and stained with
Haematoxylin and Eosin. The slides were then evaluated
and confirmed by the histopathologist from the Department
of Pathology, UKMMC. Only tissues with more than 80%
of malignant cells were subjected to total RNA isolation.
Normal tissue has to be free from malignant or inflammatory
cells. For tissues that contain less than 80% of cancer cells,
Veritas LCM system (Arcturus Engineering, Mountain View,
CA) was used to capture the isolated cells. The staining
and laser capture procedures were carried out as previously
described (17).
RNA ISOLATION
Total RNA was extracted using the RNeasy Plus Mini Kit
(QIAGEN, Hilden, Germany) and quantified using the
NanoDrop (Thermo Fisher Scientific, UK) and Agilent RNA
6000 Nano Kit (Agilent Technologies GmbH, Waldbronn,
Germany). Only samples with optical densities at 260/280
nM wave length within the range of 1.8 to 2.2 and RNA
integrity number of more than 6.5 were included in this study.
GENE EXPRESSION PROFILING
Microarray profiling of 15 tumours and five normal breast
tissues were performed using the GeneChip® Human Gene
1.0 ST array (Affymetrix Inc., Santa Clara, CA), which
contains 28,869 well annotated genes with 764,885 distinct
probes. First, cDNA was amplified using the Applause WT-
Amp ST system (NuGEN, Technologies, Inc., San Carlos,
CA). This step involved the generation of first strand
cDNA, generation of DNA/RNA heteroduplex double-
stranded cDNA, Single Primer Isothermal Amplification
(SPIA) amplification and post-SPIA modification. The
amplified ST-cDNA was further purified using QIAGEN®
MinElute® Reaction Cleanup Kit (QIAGEN, Hilden,
Germany). Only samples with optical densities at 260/280
nM wave length within the range of 1.8-2.0 and
concentration more than 250 ng/µl were selected for the
microarray. The cDNA samples underwent fragmentation,
biotin labelling and hybridisation on the GeneChip® Human
Gene 1.0 ST array. The arrays were then subjected to
automated washing and staining using the Affymetrix
Fluidics Station 400. Finally, the arrays were scanned with
GeneChip scanner.
DATA ANALYSIS
The generated microarray data was extracted using the
Affymetrix® Genotyping ConsoleTM (Affymetrix Inc., Santa
Clara, CA). These data were further analysed using the
Partek Genomics Suite 6.6 (Partek Inc., St. Louis, MO, USA).
Data normalisation utilising quantile normalisation and
robust multi-array analysis (RMA) background correction
was carried out. Differentially expressed genes with fold-
change of at least 1.5 and p-value with False Discovery
Rate < 0.05 were further analysed. Both Partek Genomics
Suite 6.6 and Database for Annotation, visualisation and
Integrated Discovery (DAVID) (18, 19) were used for the
enrichment analysis and the Pathway Studio (Ariadne,
USA) (20) was employed for pathway generation.
RESULTS
The genome-wide expression study was carried out on 15
tumour and five normal breast tissues. The epidemiological
characteristics of the patients are shown in Table 1. Using
the Partek Genomic Suite, Principal Components Analysis
(PCA) was performed to determine the distribution of the
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samples. Without eliminating the batch effect, the PCA that
acts as a quality control step, clustered the tumour and
normal cells distinctly (Figure 1). Filtering characteristic of
fold-change -1.5 to 1.5 and p-value with False Discovery
Rate < 0.05 yielded a total of 867 differentially expressed
genes. In addition, supervised hierarchical clustering
revealed 404 up-regulated and 463 down-regulated genes
(Figure 2). The top 10 up-regulated genes included CASC5,
CENPF, KIF23, DTL, MK167, TPX2, NUF2, KIF4A,
NUSAP1 and BUB1B whereas the top 10 down-regulated
genes were PAK3, B3GALT1, CX3CL1, EDN3, KCNMB1,
HOXA5, NRG1, KLHL13, TSHZ2 and IL17RD.
 Table 1. The epidemiological characteristics of the patients
Age Mean 50.6 + 8.24
Range 32-70
Tumour grade I 15%
II 40%
III 45%
Histological type Infiltrating ductal carcinoma (IDC), 90%
not otherwise specified (Nos)
Non-IDC 10%
Oestrogen Receptor Positive 75%
Negative 25%
Progesterone Receptor Positive 45%
Negative 55%
Her 2 Amplification Positive 40%
Negative 60%
Triple Negative 2 patients 10%
Figure 1. Principle component analysis clustered gene expression profiling of tumour and normal adjacent breast samples. The tumour
and normal samples were clustered distinctly. The blue circles indicate tumour samples and the red circles indicate normal samples.
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Gene Ontology (GO) is a bioinformatics tool that is
used to unify the representation of genes and gene
products’ attributes across all eukaryotes. It comprises of
three aspects that include biological process, molecular
function and cellular component (21). GO enrichment
analysis on our data under the component for biological
process showed that most of the genes were enriched in
cell proliferation followed by viral reproduction,
pigmentation, growth, rhythmic process, cell killing and
metabolic process. Meanwhile, for the molecular function,
most of the genes were enriched in chemoattractant activity,
structural molecule activity, translation regular activity,
enzyme regulator activity, electron carrier activity, catalytic
activity, transcription regulator activity, transporter activity
and binding activity. For the cellular component, most of
the genes were active in extracellular region and synapse
(Figure 3).
Enrichment analysis using DAVID bioinformatics tool
with filtering characteristic enrichment score of higher than
3, p-value < 0.05 generated a total of 74 genes that were
clustered together and highly associated with breast cancer
(18, 19). Pathway analysis revealed most of these genes
were involved in cell cycle regulation, DNA repair,
Hedgehog pathway, histone phosphorylation, TRRAP/
Tip60 chromatin remodelling and apoptosis regulation
(Table 2). Interestingly, gene BLM was involved in all the
pathways as shown in Table 2. In addition, six genes
including FANCD2, MSH2, NBN, RAD54B, TOP2A and
TOPBP1 were involved in several pathways that were
associated with DNA repair such as single-strand base
excision DNA repair, single-strand mismatch DNA repair,
direct DNA repair and double strand DNA non-homologous
repair.
Figure 2. Supervised hierarchical clustering of 15 tumours versus five normal samples display the gene expression intensity for each
genes. Samples were clustered based on 785 significant differentially expressed genes at fold change -1.5 to 1.5, p-value with FDR
< 0.05. The colour of each small box on the map represents the ratio of gene expression. Green indicates genes were up-regulated
above median; red indicates gene were down-regulated below median and black indicates gene were equal to median expression
signal. The rows represent individual genes; the columns represent individual sample.
Figure 3. Gene ontology enrichment analysis of 785 differentially expressed genes revealed the enriched biological process,
molecular function and cellular component. The number represents the enrichment score and the symbol of ‘?’ represents zero
enrichment score. The high enrichment score means that the genes were found more frequently in the particular ontology whereas
zero enrichment score means the genes did not belong to the particular ontology.
5Chin Minning et al. Asia. Pac. J. Mol. Med.
Table 2. Pathway analysis with p < 0.05 using Pathway Studio software
Pathway Genes p-value
Cell Cycle Regulation CDK1, DUSP1, CHEK1, E2F1, INHBA, EEF2, MKI67, BRCA1, KIT, 6.65E-12
FGF1, CCNA2, CCNB1, MSH2, TGFBR2, NBN, FIGF, BUB1B, CCNB2,
RAD51, TOPBP1, CCND2, MAD2L1, PTPRZ1, BLM, FANCD2,
RACGAP1, CCNE2, TOP2A, RPLP0, PRC1, NEK2, RBBP4, NEDD9,
KRT17, RAD54B, AKAP9, KPNA2, RBBP7, ANAPC7, CENPK, TUBB2B
Cell cycle CDK1, PLK1, CHEK1, PTTG1, E2F1, MKI67, BRCA1, CCNA2, BIRC5, 5.96E-11
CCNB1, TGFBR2, BUB1B, CCNB2, AURKA, CCND2, MAD2L1, BLM,
CCNE2, TOP2A, NEK2, CLSPN, AKAP9, LAMA3, ANAPC7, CENPK
Double Strand DNA BRCA1, MSH2, NBN, RAD51, TOPBP1, BLM, 0.000152
Homologous Repair FANCD2, TOP2A, RAD54B
Histone Phosphorylation ROCK1, CDK1, MSH2, NBN, AURKA, TOPBP1, BLM, FANCD2, 0.000305
TOP2A, RAD54B
Single-Strand Base Excision MSH2, NBN, TOPBP1, BLM, FANCD2, 0.000315
DNA Repair TOP2A, RAD54B
Single-Strand Mismatch MSH2, NBN, TOPBP1, BLM, FANCD2, 0.000405
DNA Repair TOP2A, RAD54B
Direct DNA Repair MSH2, NBN, TOPBP1, BLM, FANCD2, 0.000492
TOP2A, RAD54B
Double Strand DNA Non- MSH2, NBN, TOPBP1, BLM, FANCD2, 0.000677
Homologous Repair TOP2A, RAD54B
Hedgehog Pathway INHBA, MSH2, NBN, TOPBP1, CCND2, BLM, 0.003321
FANCD2, TOP2A, RBBP4, RAD54B, RBBP7, ANAPC7
TRRAP/Tip60 Chromatin MSH2, NBN, TOPBP1, MAD2L1, BLM, 0.013707
Remodeling FANCD2, TOP2A, RBBP4, RAD54B, RBBP7
Apoptosis Regulation INHBA, BIRC5, MSH2, TGFBR2, NBN, 0.024945
TOPBP1, BLM, FANCD2, TOP2A, RAD54B
DISCUSSION
Microarray studies have been extensively carried out over
the past few years to explore the gene expression
landscapes in breast cancer tissues. This technology
enables researchers to study thousands of genes
simultaneously and compare the differentially expressed
genes in an independent manner. Genes identified from
this study could serve as important prognostic indicators
and be a guide for the treatment of breast cancer. There are
limited local data that explores the complexity of this cancer.
To understand the role of differentially expressed genes
and elucidating the molecular pathways involved in breast
cancer carcinogenesis, whole genome gene expression
profile was performed in this study.
We identified 404 up-regulated and 463 down-regulated
genes. Among the top ten significant up-regulated genes,
three genes were associated with breast cancer, including
CENPF, DTL and MK167 (22-24). CENPF gene is
associated with cell proliferation (25). It encodes for
kinetochore-associated protein that is involved in the
regulation of cell division (26). Overexpression of CENPF
may lead to deregulation of cell division and uncontrolled
proliferation. A similar result was reported in a previous
study and the upregulation of CENPF was found to be
associated with poor prognosis, poor survival and a
decrease in metastasis-free survival (22). On the other hand,
DTL was found to be highly expressed not only in breast
cancer but also in other cancers (23). It might be a potential
molecular target for breast cancer treatment as silencing of
this gene may cause failure in cytokinesis and induced cell
death (23). MK167, which is an antigen identified by the
monoclonal antibody Ki-67 is a common proliferative marker
in breast cancer (24). Its expression has been reported to
be high in breast cancer and could result in an uncoordinated
cell growth and tumorigenicity (27).
For the top ten significantly down-regulated genes,
HOXA5 and NRG1 were found to be associated with breast
cancer (28, 29). HOXA5 is a transcription factor that is
involved in apoptosis induction (30). Down-regulation of
this gene may lead to cell cycle aberration and this could
promote breast cancer carcinogenesis (28). Meanwhile,
NRG1 is a tumour suppressor gene and its expression can
stimulate apoptosis (29, 31). NRG1 gene was found to be
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frequently silenced in many breast cancers (29) including
the samples in our current study.
We further compared our results with the genes listed
in the Mammaprint assay (Agendia, Amsterdam, The
Netherlands) to check whether there were any overlapping
genes. A total eight genes (8 out of 74 genes in the assay)
including C9orf30, CCNE2, CENPA, DTL, ECT2, MELK,
NUSAP1, PRC1 and DIAPH3 were identified to be
overlapped. Notably, all of these genes were overexpressed
in our samples and their biological functions reflect the
hallmarks of cancer as shown in a previous report (32).
There are eight hallmarks of cancer including evading
apoptosis, self-sufficiency in growth signals, insensitivity
to anti-growth signals, limitless replicative potential, tissue
invasion and metastasis, sustained angiogenesis,
deregulating cellular energetic and avoiding immune
destruction (33, 34). Interestingly, most of the overlapped
genes (CCNE2, CENPA, DTL, ECT2, NUSAP1 and PRC1)
were involved in the hallmark of limitless replicative
potential. Aberration in the expression of these genes would
contribute to the uncontrolled cell cycle (32). Meanwhile,
MELK reflects the hallmark of evading apoptosis,
insensitivity to antigrowth signal and self-sufficiency in
growth signal (32). Overexpression of this gene could lead
to abnormal proliferation and oncogenic transformation
during breast carcinogenesis (32). DIAPH3 was included
under the hallmark of tissue invasion and metastasis (32).
It regulates the dynamics of microtubules, actin remodelling
and cell movement that lead to the escape of cells to distant
sites (32, 35).
We also compared our results with the genes listed in
the Oncotype DX assay (Genomic Health, Redwood City,
California). Out of 21 genes in the assay, three genes
(CCNB1, MYBL2 and MK167) were found to overlap.
CCNB1 is involved in mitosis regulation (36) and high
expression leads to abnormal mitosis which may contribute
to breast cancer progression. Overexpression of this gene
was also associated with poor survival in breast cancer
(37). Meanwhile, MYBL2 is a transcription factor that
regulates the expression of genes involved in cancer
progression (38).
In general, aberration in the molecular pathways such
as cell cycle regulation could lead to the uncontrolled cell
proliferation. In the current study, most of the clustered
genes were involved in the cell cycle regulation. Genes
such as CCNB1, E2F1 and CDK1 are known to be crucial
genes that regulate cell cycle and promote breast
carcinogenesis (39, 40). BLM is involved in all the pathways
shown in Table 2. A previous study showed that BLM plays
an important role in the homologous recombination pathway
for DNA double-strand break repair (41). In addition, genes
such TOP2A and TOPBP1 were involved in several
pathways that are associated with DNA repair. These genes
were reported to be associated with breast cancer (42, 43).
Aberration in these genes might cause failure in the DNA
repair, aberrant DNA replication and disturbance in cell
division in breast cancer.
In conclusion, our study successfully examined the
whole genome gene expression profile in breast cancer from
our local Malaysian patients. These findings highlighted
the significant genes and revealed the biological pathways
that could contribute additional knowledge to understand
the underlying breast carcinogenesis.
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